Inclusion Criteria:

   - Subject has short bowel syndrome, defined as 50% or less of expected bowel length
   based on subject age and/or height, and measured at the time of the subject's prior
   intestinal resection.

   - Minimum residual bowel length of 10 cm.

   - Male or female patients aged 18 to 50 years inclusive

   - Subject has scheduled open abdominal procedure for different indication than study
   device (i.e., ostomy take-down, stoma-take-down, open liver biopsy, and procedures to
   correct the following: bowel obstruction, strictures, adhesions).

   - The subject, parent or legal guardian of the subject is able to read, understand, and
   is willing to provide informed consent.

   - The subject or parent or legal guardian of the patient is able to understand the
   requirements of the study and is willing to bring the subject to all clinic visits and
   complete all study related procedures (as determined by the investigator).

Exclusion Criteria:

   - Previously performed intestinal resection and/or bowel lengthening procedure < 6
   months from screening visit.

   - Ultra-short bowel syndrome defined as less than 10 cm of bowel length.

   - Diagnosed Inflammatory bowel disease-unclassified (not Crohn's or ulcerative colitis)

   - Evidence of active or prior Crohn's disease.

   - Primary intestinal failure (i.e., without loss or resection of intestinal tissue).

   - Coagulopathy, as defined by INR > 1.4 or platelets < 100.

   - Known immunocompromised status including, but not limited to, individuals who have
   undergone organ transplantation, chemotherapy or radiotherapy within the past 12
   months, who have clinically significant leukopenia, who are positive for the human
   immunodeficiency virus (HIV) or whose immune status makes the subject a poor candidate
   for clinical trial participation in the opinion of the Investigator.

   - Subject is determined by the investigator to be unsuitable for participation in this
   trial for any reason.